Sildenafil Citrate for Treatment of Growth-restricted Fetuses

• Status: Unknown status
• Trial end date: 2017-10-01
• Target enrollment: 0
• Participant gender: Female

Summary

The aim of this study is to assess the effect of Sildenafil citrate therapy on neonatal outcomes in women with fetal growth restriction.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Ain Shams University
• Treatments: Citric Acid; Sildenafil Citrate

Criteria

Inclusion Criteria:

• Maternal age ranging from 20-40 years.

• Gestational age 28-37 weeks.

Exclusion Criteria:

• Obese patients (BMI >30 kg/m2).

• Patients with medical disorders: cardiac diseases, pulmonary diseases, liver disease, renal disease, previous history of seizures, hearing loss.

• Drug interactions, such as users of any vasodilator agents, omeprazole, clarithromycin and amoxicillin.

• Fetal distress.

• Pregnancy of multiple fetuses.

• Congenital fetal malformation or chromosomal abnormalities.

• Diastolic blood pressure more than 110 mmHg.

• Hypersensitivity to the drug.